Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT)
Richard D. Carvajal(Northwell Health), Paul Nathan(Mount Vernon Hospital), Gary K. Schwartz(Baylor University Medical Center), Zhongwu Lai(AstraZeneca (United States)), Pascal Wolter(KU Leuven), Josep M. Piulats(Institut Català d'Ornitologia), Jacob Schachter, Elaine Kilgour(Leiden University Medical Center), Ellen Kapiteijn(Leiden University Medical Center), T.R. Jeffry Evans(Leiden University Medical Center), Bartosz Chmielowski(UCLA Health), Alexander N. Shoushtari(Memorial Sloan Kettering Cancer Center), Lauris Gastaud(Leiden University Medical Center), Manuel Rodrigues(Inserm), G Mariani(Leiden University Medical Center), Carola Berking(Universitätsklinikum Erlangen), Shirley Spratt(Leiden University Medical Center), Dana Ghiorghiu(AstraZeneca (United Kingdom)), Gerald P. Linette(University of Pennsylvania), Paul B. Chapman(Memorial Sloan Kettering Cancer Center), Anthony M. Joshua(St Vincent's Hospital Sydney), Peter Barker(Leiden University Medical Center), Véronique Cocquyt(Leiden University Medical Center), Stephen Jay Frank(Leiden University Medical Center), Delyth Clemett(Leiden University Medical Center), Susan Lovick(Leiden University Medical Center), Sophie Piperno‐Neumann(Institut Curie)
Cited by 274
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET
|Nature Medicine|2012|3.7k
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k